Wearable device to measure heart output in people with congenital heart disease
Tests UltraTrac, a wearable monitor, in people with congenital heart disease.
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
- Status
- Not yet recruiting
- People taking part
- 70 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- UltraTrac
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with congenital heart disease (a heart problem present from birth). They must be having a planned heart catheter test, a heart MRI, or a stay in the cardiac intensive care unit. The trial tests UltraTrac, a wearable device that measures how much blood the heart pumps.
- Age
- 0 to 80 years old.
- Sex
- All sexes can join.
- Disease stage
- Congenital heart disease of any type, repaired or not repaired. This includes single ventricle, valve disease, holes between heart chambers and conotruncal anomalies. Participants must weigh at least 2 kg (4 lb).
- Earlier treatment
- Participants must have a planned heart catheter test, a heart MRI, or a cardiac intensive care stay where heart drugs (vasoactive medication) are expected to be started or changed.
Main reasons for not taking part
- Allergy or past skin reaction to sticky electrodes or ultrasound gel
- Skin damage, wound or infection where the device would go
- Unstable heart and blood flow at enrolment, as judged by the treating doctor
- Known neck artery (carotid) problem or past carotid surgery
- Pregnant people, prisoners, adults who cannot give consent, and military or DoD staff
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- 0-80 years old
- Participant weight of at least 2 kg
- Diagnosis of congenital heart disease of any anatomic type, including but not limited to repaired or unrepaired single ventricle physiology, biventricular congenital heart disease, valvular disease, septal defects, and conotruncal anomalies
- Clinically indicated cardiac catheterization, cardiac MRI, or cardiac intensive care unit admission during the study enrollment period
- For Arm 1: scheduled to undergo hemodynamic cardiac catheterization during which thermodilution and/or direct Fick cardiac output measurements will be performed as part of standard clinical care
- For Arm 2: scheduled to undergo cardiac MRI during which CMR-derived cardiac output measurement will be obtained as part of the clinical protocol
- For Arm 3: admitted to the cardiac intensive care unit and anticipated to require initiation or titration of vasoactive medication as part of standard clinical management
- Parental permission, and assent when applicable, obtained from at least one parent or legally authorized representative
Who cannot take part
- Known allergy or prior skin reaction to adhesive electrodes or ultrasound gel
- Known carotid artery abnormality, prior carotid surgery, or anatomic variant that would preclude reliable carotid Doppler signal acquisition
- Skin breakdown, wound, or infection at any proposed electrode or probe placement site that would preclude safe device application
- Hemodynamic instability at the time of enrollment that, in the judgment of the treating clinician, would preclude safe participation in research procedures
- Participant or family refusal to participate or inability to obtain informed consent or parental permission
- Pregnant women/persons
- Fetuses
- Prisoners
- Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent
- Employees of the researcher
- Students of the researcher
- Active members of the military or DoD personnel
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 80 years old?
Where in United States
- M Health Fairview University of Minnesota Masonic Children's HospitalMinneapolis, United StatesContact: Juan Carlos SamayoaNot yet recruiting
About the trial
What the trial wants to find out
This pilot feasibility study will evaluate UltraTrac, an investigational noninvasive wearable device for continuous cardiac output monitoring, in patients with congenital heart disease.
Read full original descriptionShow less
UltraTrac integrates impedance cardiography and carotid Doppler ultrasound to estimate cardiac output. Participants undergoing clinically indicated cardiac catheterization, cardiac MRI, or cardiac intensive care unit monitoring will have UltraTrac measurements collected during routine clinical care.
UltraTrac measurements will be compared with reference standard or clinical hemodynamic measurements, including thermodilution, direct Fick method, cardiac magnetic resonance imaging-derived cardiac output, and clinical hemodynamic assessments before and after vasoactive medication changes. UltraTrac data will not be used to guide clinical decision-making.
The 3 groups in the trial
- Cardiac Catheterization Laboratory UltraTrac MonitoringTreatment being tested
Participants undergoing clinically indicated cardiac catheterization will have UltraTrac measurements obtained and compared with thermodilution and/or direct Fick cardiac output measurements obtained as part of standard clinical care.
Treatment: UltraTrac
- Cardiac MRI UltraTrac MonitoringTreatment being tested
Participants undergoing clinically indicated cardiac MRI will have UltraTrac measurements obtained near the time of cardiac MRI and compared with CMR-derived cardiac output measurements obtained as part of standard clinical care.
Treatment: UltraTrac
- Cardiac Intensive Care Unit UltraTrac MonitoringTreatment being tested
Participants admitted to the cardiac intensive care unit will have UltraTrac measurements obtained before and after clinically indicated introduction or titration of vasoactive medications. UltraTrac trending will be compared with concurrent clinical hemodynamic assessments.
Treatment: UltraTrac
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- UltraTrac for Noninvasive Cardiac Output Monitoring in Patients With Congenital Heart Disease: A Multi-Setting Pilot Feasibility Study
- Plain-language title
- Wearable device to measure heart output in people with congenital heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07866573, who can take part
- Record updated
- 3 November 2026